Vera Therapeutics, Inc.
VERA
$28.82
-$0.48-1.64%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 149.35% | 67.73% | 39.95% | 28.65% | -9.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 80.98% | 128.91% | 69.97% | -0.47% | -19.51% |
| Operating Income | -80.98% | -128.91% | -69.97% | 0.47% | 19.51% |
| Income Before Tax | -69.27% | -131.95% | -67.19% | 5.61% | 20.91% |
| Income Tax Expenses | 0.00% | -- | -- | -- | 0.00% |
| Earnings from Continuing Operations | -69.27% | -131.95% | -67.19% | 5.61% | 20.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.27% | -131.95% | -67.19% | 5.61% | 20.91% |
| EBIT | -80.98% | -128.91% | -69.97% | 0.47% | 19.51% |
| EBITDA | -80.80% | -128.86% | -67.10% | -- | 19.42% |
| EPS Basic | -23.98% | -87.42% | -35.24% | 30.25% | 50.67% |
| Normalized Basic EPS | -23.98% | -87.46% | -35.39% | 30.25% | 50.57% |
| EPS Diluted | -23.98% | -87.42% | -35.24% | 30.25% | 50.67% |
| Normalized Diluted EPS | -23.98% | -87.46% | -35.39% | 30.25% | 50.57% |
| Average Basic Shares Outstanding | 36.53% | 23.75% | 23.63% | 35.32% | 60.32% |
| Average Diluted Shares Outstanding | 36.53% | 23.75% | 23.63% | 35.32% | 60.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
